Quick Answer
Elicio Therapeutics, Inc. reported Net Income of -$39.57 million for fiscal year 2025.
Elicio Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$39.57M | +23.8% |
| 2024 | -$51.90M | -47.5% |
| 2023 | -$35.20M | -24.8% |
| 2022 | -$28.21M | +48.3% |
| 2021 | -$54.57M | +31.9% |
| 2020 | -$80.11M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$10.08M | +46.5% | +4.5% |
| June 30, 2025 | -$10.56M | -46.1% | +5.8% |
| March 31, 2025 | -$11.21M | +5.2% | +40.5% |
| September 30, 2024 | -$18.84M | -76.7% | -160.6% |
| June 30, 2024 | -$7.23M | +4.4% | +38.9% |
| March 31, 2024 | -$11.83M | -47.3% | -11.0% |
| September 30, 2023 | -$10.66M | -48.1% | -41.0% |
| June 30, 2023 | -$7.56M | -3.6% | +5.9% |
- Elicio Therapeutics, Inc. showed an increase of +23.8% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Elicio Therapeutics, Inc.’s net income has grown by 50.6% (from -$80.11 million to -$39.57 million).
- The most recent figure is from Elicio Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: